Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors DOI Creative Commons
Ichiro Yamauchi, Daisuke Yabe

European Thyroid Journal, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Immune checkpoint inhibitors (ICIs) frequently cause immune-related adverse events (irAEs), with thyroid irAEs being the most common endocrine-related irAEs. The incidence of overt ranged 8.9–22.2% in real-world settings, typically triggered by antibodies against PD-1 and PD-L1 rarely anti-CTLA-4 alone. representative clinical course involves biphasic changes function, transient thyrotoxicosis subsequent persistent hypothyroidism. identified risk factors for include presence autoantibodies, uptake 18F-FDG-PET, prior use tyrosine kinase (TKIs), high BMI, TSH levels. There is evidence that are associated good prognosis, at least non-small cell lung cancer. Although features have been well clarified, management strategies require further refinement. Routine monitoring function every 4 to 6 weeks during ICI therapy recommended early detection While generally requires observation only, hypothyroidism should be promptly treated levothyroxine replacement. Continuation feasible patients irAEs, provided their overall health remains stable. However, these were largely based on experience monotherapy. As combination therapies developed as first-line treatments, antitumor agents may modify For example, cytotoxic can delay onset while TKIs often linked early-onset hypothyroidism, independent use. Given increasing diversity complexity cancer immunotherapy, it essential vigilantly screen

Language: Английский

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 DOI Creative Commons
Julie R. Brahmer, Jong-Seok Lee, Tudor‐Eliade Ciuleanu

et al.

Journal of Clinical Oncology, Journal Year: 2022, Volume and Issue: 41(6), P. 1200 - 1212

Published: Oct. 12, 2022

We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus ipilimumab improved overall survival (OS) versus chemotherapy patients with metastatic non-small-cell lung cancer, regardless of tumor programmed death ligand 1 (PD-L1) status.Adults stage IV/recurrent cancer without EGFR mutations or ALK alterations and PD-L1 ≥ 1% < (n = 1739) were randomly assigned. Patients assigned to first-line ipilimumab, alone, chemotherapy. chemotherapy, End points included exploratory for efficacy, safety, quality life.At a minimum follow-up 61.3 months, OS rates 24% 14% (PD-L1 1%) 19% 7% 1%). The median duration response was 24.5 6.7 months 19.4 4.8 Among surviving 5 years, 66% 64% off initiating subsequent systemic anticancer treatment by the time point. Survival benefit continued after discontinuation because treatment-related adverse events, rate 39% (combined populations). Quality life survivors treated similar that general US population through follow-up. No new safety signals observed.With all immunotherapy 3 increased survivorship including long-term, durable clinical expression. These data support as an effective cancer.

Language: Английский

Citations

209
Clinical cancer immunotherapy: Current progress and prospects DOI Creative Commons
Chenglong Liu, Mengxuan Yang, Daizhou Zhang

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Oct. 11, 2022

Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and robust therapeutic potential in practice. It can significantly improve progression-free survival overall survival. Following surgery, radiotherapy, chemotherapy, targeted therapy, cancer treatment now entered the age of immunotherapy. Although immunotherapy remarkable efficacy, it also suffers from limitations such as irAEs, cytokine storm, low response rate, etc. In this review, we discuss basic classification, research progress, Besides, by combining resistance mechanism with analysis combination give our insights into development new anticancer strategies.

Language: Английский

Citations

145
Immune-related adverse events of immune checkpoint inhibitors: a review DOI Creative Commons
Qinan Yin,

Liuyun Wu,

Lizhu Han

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: May 25, 2023

Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has entered a new era, and response rate survival of many cancers have also been improved. Despite success immune checkpoint inhibitors, resistance limits number patients who can achieve lasting response, immune-related adverse events complicate treatment. The mechanism (irAEs) is unclear. We summarize discuss mechanisms action different types their possible mechanisms, describe strategies targets for prevention therapeutic interventions to mitigate them.

Language: Английский

Citations

139
Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors DOI Creative Commons
Liangliang Xu, Chang Zou, Shanshan Zhang

et al.

Journal of Hematology & Oncology, Journal Year: 2022, Volume and Issue: 15(1)

Published: July 7, 2022

The development of combination immunotherapy based on the mediation regulatory mechanisms tumor immune microenvironment (TIME) is promising. However, a deep understanding immunology must involve systemic environment (STIE) which was merely illustrated previously. Here, we aim to review recent advances in single-cell transcriptomics and spatial for studies STIE, TIME, their interactions, may reveal heterogeneity responses as well dynamic changes essential treatment effect. We evidence from preclinical clinical related significance overall survival, through different immunomodulatory pathways, such metabolic neuro-immunological pathways. also evaluate interactions after local radiotherapy or combined immunotherapy. focus our lung cancer, hepatocellular carcinoma, nasopharyngeal aiming reshape STIE TIME enhance efficacy.

Language: Английский

Citations

113
Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases DOI
Alice Tison, Soizic Garaud, Laurent Chiche

et al.

Nature Reviews Rheumatology, Journal Year: 2022, Volume and Issue: 18(11), P. 641 - 656

Published: Oct. 5, 2022

Language: Английский

Citations

103
Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data DOI
Deniz Can Güven, Enes Erul, Yunus Kaygusuz

et al.

Supportive Care in Cancer, Journal Year: 2023, Volume and Issue: 31(11)

Published: Oct. 11, 2023

Language: Английский

Citations

98
Immune Checkpoint Inhibitor Therapy in Oncology DOI Creative Commons
Sean Tan, Daphne Day, Stephen J. Nicholls

et al.

JACC CardioOncology, Journal Year: 2022, Volume and Issue: 4(5), P. 579 - 597

Published: Dec. 1, 2022

Language: Английский

Citations

96
Immune mechanisms of toxicity from checkpoint inhibitors DOI Creative Commons
S. Jennifer Wang, Stephanie K. Dougan, Michael Dougan

et al.

Trends in cancer, Journal Year: 2023, Volume and Issue: 9(7), P. 543 - 553

Published: April 27, 2023

Immunotherapy has changed the treatment landscape for cancer over past decade. Inhibitors of immune checkpoint proteins cytotoxic T lymphocyte antigen (CTLA)-4, programmed death (PD)-1, and PD ligand 1 (PD-L1) can induce durable remissions in a subset patients with metastatic disease. However, these treatments be limited by inflammatory toxicities that affect any organ system body some cases life threatening. Considerable progress been made understanding drivers as well effective management strategies. Further research into molecular cellular mechanisms drive toxicity will enable better prediction development optimized therapies avoid interfering antitumor immunity. In this review, we discuss our current from inhibitors (ICIs) propose optimal strategies toxicities.

Language: Английский

Citations

90
Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin DOI Creative Commons
Mario E. Lacouture, Anisha B. Patel, Jonathan E. Rosenberg

et al.

The Oncologist, Journal Year: 2022, Volume and Issue: 27(3), P. e223 - e232

Published: Jan. 24, 2022

Enfortumab vedotin is a first-in-class Nectin-4-directed antibody-drug conjugate approved by the US Food and Drug Administration for treatment of patients with locally advanced or metastatic urothelial cancer (la/mUC) previously treated platinum-based chemotherapy programmed death receptor-1/programmed death-ligand 1 (PD-1/L1) inhibitor, la/mUC who are ineligible cisplatin-based have received one more prior lines therapy. only drug to demonstrated survival benefit versus in randomized controlled trial PD-1/L1 inhibitor. The development dermatologic events following administration enfortumab anticipated given expression Nectin-4 epidermal keratinocytes skin appendages (eg, sweat glands hair follicles). There potential rare but severe possibly fatal cutaneous adverse reactions, including Stevens-Johnson syndrome toxic necrosis, as described boxed warning prescribing information vedotin. This manuscript describes presumed pathophysiology manifestations reactions related vedotin, presents recommendations prevention treatment, provide oncologists other healthcare providers an awareness these best anticipate manage them.

Language: Английский

Citations

88
Cardiovascular complications of immune checkpoint inhibitors for cancer DOI Open Access
Franck Thuny, Jarushka Naidoo, Tomas G. Neilan

et al.

European Heart Journal, Journal Year: 2022, Volume and Issue: 43(42), P. 4458 - 4468

Published: Aug. 30, 2022

Abstract Over the last decade or so, there has been a paradigm shift in oncologic care of patients with range solid tumour and haematologic malignancies, away from traditional cytotoxic chemotherapy towards personalized cancer treatments, using both targeted therapy immunotherapy. This contributed to remarkable sustained increase number survivors longevity diagnosis. review will focus on cardiovascular effects immune checkpoint inhibitors present background inhibition for cancer, epidemiology, potential mechanisms, insights into biology, diagnostic therapeutic approach cases. Our understanding needs improve. However, evolution necessarily be rapid. Initial observations noted that inhibitor can lead fulminant myocarditis. Recent reports have expanded effect system include an cardiac dysfunction without myocarditis, arrhythmias, venous thromboembolic disease, accelerated atherosclerosis, atherosclerosis-related events. The association between these events is not only limited occurring within first few weeks after starting but also occur months years therapy. latter observation especially relevance those treated adjuvant neoadjuvant There recognition currently approved therapies mechanisms adverse effects, who at risk, what we do about it.

Language: Английский

Citations

74